FDA Deems Mircera “Approvable” For Anemia Pending Cardio-Renal Committee Outcome
This article was originally published in The Pink Sheet Daily
Executive Summary
No further clinical trials involving the long-acting erythropoiesis-stimulating agent are anticipated, Roche says.
You may also be interested in...
Roche Hedges On U.S. Launch Of Mircera With November FDA Action Date Expected
Decision in Amgen’s patent infringement case against Roche over the continuous erythropoiesis receptor activator is expected in October.
Roche Hedges On U.S. Launch Of Mircera With November FDA Action Date Expected
Decision in Amgen’s patent infringement case against Roche over the continuous erythropoiesis receptor activator is expected in October.
Amgen Knocks Roche In Early Round Of EPO Court Fight
Federal judge rules that Roche’s EPO product Mircera infringes a key Amgen patent, although trial is still set for Sept. 4.